Lessons Learned from Monitoring Adeno-Associated Virus-9 Neutralizing Antibody (AAV9-NAb) Seroconversion in a Cohort of Cynomolgus Macaques (Macaca fascicularis)

The purpose of this study was to track seroconversion in a cohort of 12, pair-housed, macaques that were previously screened negative for adeno-associated virus-9 neutralizing antibody (AAV9-NAb). Over a 6-month period, specific biosecurity strategies were implemented with the intention of understanding if following defined protocols could play a role in preservation of AAV9-NAb negative status. AAV9-NAb-negative animals were selected for shipment to the facility approximately 2 months after the initial screening. After arrival, animals were paired and housed in a single room with a dedicated housing corridor, cage wash, and equipment. They were then screened for AAV9-NAb status monthly by 2 different labs to confirm results and ascertain potential for variation of results. Upon initial screening at the facility (within one week of arrival), 2 of the 12 NHPs that were seronegative before shipment had seroconverted to AAV9-NAb positive status. The positive animals and their negative partners were moved to a different room but remained within the same isolated corridor with the same biosecurity practices. Serum that was taken on a monthly basis was also used to screen other AAVs. At the end of the 6-month period, AAV9 NAb status did not change from the time the animals were initially screened on site until the end of the study. Paired animals that were cohoused in the same cage with a positive partner did not seroconvert. Although a control group was not used to validate that biosecurity practices played a role in mitigating seroconversion, unpublished data from a facility employing less restricted biosecurity strategies suggest that the seroconversion process involves a more intricate process.

Authors

Institutions

Publication Details

Journal
Journal of the American Association for Laboratory Animal Science
Published
2025-08-09
DOI
https://doi.org/10.30802/aalas-jaalas-24-163
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lessons Learned from Monitoring Adeno-Associated Virus-9 Neutralizing Antibody (AAV9-NAb) Seroconversion in a Cohort of Cynomolgus Macaques (Macaca fascicularis)

Rosemary Santos, Arpana Khatri, Mikele D. Simkins, Maureen Hargaden et al.
1 links
Journal of the American Association for Laboratory Animal Science
Virus-based gene therapy research
article

Lessons Learned from Monitoring Adeno-Associated Virus-9 Neutralizing Antibody (AAV9-NAb) Seroconversion in a Cohort of Cynomolgus Macaques (Macaca fascicularis)

Rosemary Santos, Arpana Khatri, Mikele D. Simkins, Maureen Hargaden, Kate E. Breyer, Judith Franco, Rajeev Dhawan, Jan Bernal, Suryanarayan Somananthan, Conner Balzer, Marla Bazile
article en

Abstract

The purpose of this study was to track seroconversion in a cohort of 12, pair-housed, macaques that were previously screened negative for adeno-associated virus-9 neutralizing antibody (AAV9-NAb). Over a 6-month period, specific biosecurity strategies were implemented with the intention of understanding if following defined protocols could play a role in preservation of AAV9-NAb negative status. AAV9-NAb-negative animals were selected for shipment to the facility approximately 2 months after the initial screening. After arrival, animals were paired and housed in a single room with a dedicated housing corridor, cage wash, and equipment. They were then screened for AAV9-NAb status monthly by 2 different labs to confirm results and ascertain potential for variation of results. Upon initial screening at the facility (within one week of arrival), 2 of the 12 NHPs that were seronegative before shipment had seroconverted to AAV9-NAb positive status. The positive animals and their negative partners were moved to a different room but remained within the same isolated corridor with the same biosecurity practices. Serum that was taken on a monthly basis was also used to screen other AAVs. At the end of the 6-month period, AAV9 NAb status did not change from the time the animals were initially screened on site until the end of the study. Paired animals that were cohoused in the same cage with a positive partner did not seroconvert. Although a control group was not used to validate that biosecurity practices played a role in mitigating seroconversion, unpublished data from a facility employing less restricted biosecurity strategies suggest that the seroconversion process involves a more intricate process.

Journal of the American Association for Laboratory Animal ScienceVol. 64(6)
Amgen (United States) (US), Charles River Laboratories (Netherlands) (NL), Pfizer (United States) (US), Voyager Therapeutics (United States) (US), Charles River Laboratories (United States) (US), Solidus Biosciences (United States) (US)
Openalex Percentile: Top 77%
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.